UnknownNot Applicable

Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs

Egypt52 participantsStarted 2023-03-20

Plain-language summary

The aim of the study is to evaluate the expression pattern of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes in Myeloproliferative neoplasms as a possible indicator of disease progression and as a potential therapeutic target

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: The study will be carried out on patients newly diagnosed with one of the myeloproliferative neoplasms based on WHO Criteria for diagnosis of MPNs whether males or females and of any age. Exclusion Criteria: * Other malignancies. * Patients on chemotherapy or radiotherapy. * Autoimmune diseases.

What they're measuring

Expression of Heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and Heterogeneous nuclear ribonucleoprotein K (HNRNPK) genes in myeloproliferative neoplasms (MPNs)

Timeframe: two years

Trial details

NCT IDNCT05782985

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-03-20

Contact for this trial

Alaa Elminshawy, MD, MSc

01128892117 alaa.elminshawy@med.aun.edu.eg

View on ClinicalTrials.gov More Myeloproliferative Neoplasms (MPNs) trials